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ABSTRACT  
OBJECTIVE  
The objective of this selective EBM review is to determine whether or not laser therapy is 
effective at relieving pain in adult patients with recurrent aphthous stomatitis. 
STUDY DESIGN  
Systematic review of three randomized controlled trials published in 2009, 2009, and 2013.  
DATA SOURCES  
Three randomized controlled trials were obtained using PubMed.  
OUTCOMES MEASURED  
The symptom of pain was measured for improvement by patient survey of visual analog pain 
scales.  
RESULTS  
Prasad et al. (2013), Tezel et al. (2009), and Zand et al. (2009) all demonstrated improvement in 
a majority of the subjects’ pain relief from treatment with laser therapy. 
CONCLUSION  
Evidence to support the efficacy of laser therapy as a treatment of pain relief for recurrent 
aphthous stomatitis in adults is strong at this point in time, due to a relevant subject population, 
fixed standard of measurement, and a wide spectrum of subject age.  The data strongly supports 
the efficacy of laser therapy as a superior method of pain relief for adult patients suffering from 
recurrent aphthous stomatitis.  
KEY WORDS 
Laser therapy and aphthous stomatitis 
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INTRODUCTION 
Recurrent oral aphthous stomatitis is a common disorder that affects up to 25% of the 
population in the United States.1 The etiology behind recurrent aphthous stomatitis (RAS) is 
idiopathic, but it is believed there is a genetic predisposition.1,2  RAS can be classified into three 
clinical forms; minor recurrent aphthous stomatitis, major recurrent aphthous stomatitis, or 
herpetiformis.3 Minor RAS comprise the majority of cases and are involved in 80%-90% of 
RAS.3 Minor recurrent aphthous stomatitis are classified as being less then 1 centimeter in 
diameter and last anywhere from 7-14 days.3  The current theory on how these ulcers appear 
involves cell mediated mechanisms, although the exact immunopathogenesis is uncertain.4  RAS 
is routinely diagnosed based on a detailed history and physical examination.  There is currently 
no cure for recurrent oral aphthous ulcers and there have been few investigations into treatment 
options.  Aphthous ulcers are not overtly dangerous to one’s health, but can be quite painful, 
with pain usually subsiding after 4-5 days.3 This systematic review is aimed at determining 
whether or not laser therapy is an effective option at relieving pain in adult patients with 
recurrent oral stomatitis.  This paper evaluates three randomized control trials comparing pain 
relief using laser therapy versus placebo and topical medication options for recurrent ulcers.     
In the United States, there is no clear cut answer to how many individuals are affected by 
oral aphthous stomatitis.  Since there is no known cure for RAS and because outbreaks can occur 
so frequently, many afflicted patients do not seek care for the pain they endure from RAS.  
Because of this, there is not an exact statistical number of patients that can be identified as 
having RAS.  Estimates range anywhere from 5%-25% of the population in the United States are 
affected by aphthous stomatitis.2,3 By extrapolating 5% of the population in the United States, it 
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is estimated that upwards of ten million people are affected by recurrent aphthous stomatitis.3 
Many afflicted patients do not seek medical care due to the lack of a cure or the fact that ulcers 
resolve on their own after up to two weeks of pain.  Although many have spontaneous healing of 
ulcers within ten to fourteen days, treatment is sought by many individuals to reduce the time it 
takes RAS to heal and the pain that is associated with ulcerations.  Reducing healing time and 
pain returns the patient’s ability to speak, eat, and swallow, hence improving their quality of 
life.1  Reports estimate anywhere between 5-25% of the population in the United States are 
affected by RAS and most common age range is between 10 to 30 years old.2 RAS have been 
reported in all races and there is a slight female predominance.4  Most patients with RAS are 
otherwise healthy and do not face an increased morbidity or mortality rate.  The challenges faced 
with finding a precipitating event for RAS are its nonspecific histological features and a lack of 
ability to reproduce the causes.2 Predisposing factors for RAS are believed to include; oral 
trauma, genetic background, allergic agents, or nutritional deficiencies.  RAS has been associated 
with deficits of vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, zinc, iron; Crohn’s 
disease, celiac disease, Behcet’s syndrome, and immunodeficiency.1   
Current management of Recurrent oral aphthous stomatitis is multifaceted.  Currently 
there is no preferred management method.  Numerous treatment modalities have been used to 
manage RAS.  The current goal of therapy is to lessen the pain and duration of ulcers and to 
avoid local trauma that may cause them to return.  Management conventionally consists of 
systemic medications, topical medications, or corticosteroids.  Newer methods of treatment have 
included acupuncture, psychotherapy, and most recently laser therapy.     
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OBJECTIVE 
 The objective of this systematic review is to determine whether or not laser therapy is 
effective at relieving pain in adult patients with recurrent aphthous stomatitis. 
METHODS 
 This review is comprised of three randomized controlled clinical trials that meet specific 
criteria for the comparison of laser therapy for pain relief in patients with recurrent aphthous 
ulcers.  The first trial was a randomized control trial study comparing pain relief between laser 
therapy and a topical corticosteroid.  The corticosteroid used was triamcinolone acetonide 0.1%.  
The second trial was a randomized control trial, single blind study, that examined the efficacy of 
laser therapy versus an active placebo.  The third RCT single blind study also compared pain 
relief between laser therapy and placebo in patients with recurrent aphthous ulcers.  The 
populations within all of these trials consisted of adults over the age of 18 who had recurrent 
aphthous ulcerations that had appeared within 72 hours of the study.  The populations excluded 
from these studies were patients under the age of 18 years old, those with history of systemic 
disease related to RAS, or RAS that appeared more then 72 hours before the study began.   
 Keywords used in the research for these studies were laser therapy and aphthous 
stomatitis.  All articles used in this research were peer-reviewed journals and were found via 
PubMed.  Selection of the articles researched had to meet several inclusion criteria including: 
relevance to the proposed clinical question, publication date in the year 2000 or later, and the 
articles had to be presented as a patient oriented outcome studies.  Exclusion criteria included 
articles published prior to the year 2000, articles that focused on disease oriented outcomes 
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versus patient oriented outcomes, or articles that included patients suffering from any other type 
of pain.  Statistics used within these studies used p-value, confidence intervals, and standard 
deviation.  Below, Table 1 displays the demographics and characteristics of the studies reviewed 
and used. 
Table 1: Demographics and Characteristics of included studies 
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OUTCOME MEASURED 
 All three studies measured the desired outcome of pain reduction using a 10 centimeter 
visual analog pain scale that ranged from 0 to 10.  Participants in all studies were informed that 
the left most side of the scale assigned with a 0 signaled no pain or discomfort and the scale 
elevated sequentially to 10 on the right most side of the scale indicating the worst pain or most 
severe discomfort.  In the Tezel study, pain was initially assessed pretreatment and then post 
treatment on days 1, 4, and 7.  All assessments were carried out in the same clinic, in an area free 
of music, noise, or conversation.  In the Prasad study, pain was assessed prior to treatment, 
immediately after treatment, and twenty-four hours post treatment.  Pain was assessed in the 
Zand study before treatment, immediately after treatment, and post treatment at intervals of 4 
hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, and 96 hours.   
RESULTS 
 In all three randomly controlled trials, the efficacy of laser therapy is compared to a 
placebo or an alternate medication.  In the Tezel study, a total of 20 patients entered the study 
and all patients completed the study.  The exclusion parameters for this study included patients 
who were pregnant or breastfeeding, those with concurrent clinical conditions that could pose a 
health risk, those with ulcers that manifested as a result of a systemic disease process, those 
currently undergoing treatment for their ulcers or have used nonsteroidal anti-inflammatory 
drugs or antihistamines within one month of the study, and those under the age of 18 years old.  
The patients in this study were well matched in demographics including age, sex, medical 
history, baseline ulcer location, ulcer history, and number of ulcers.  A randomizing table was 
used to split patients into two groups.  The two types of therapy were allocated randomly to 
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patients using the randomizing table.  Group 1 was treated with triamcinolone acetonide 0.1%, 
applied to the ulcers three times a day for one week.  Group 2 was treated once using an 
Nd:YAG laser for 2-3 minutes.  Prior to treatment, mean ulcer pain was collected and was found 
to be even between the two groups.  Day one post treatment, the patients treated with laser 
therapy (group 2) saw their pain decrease drastically.  By day 4, the patients in group 2 had their 
pain almost completely vanish.  By the end of the study on day 7, patients in group 2 had no 
pain.  Patients treated with a topical corticosteroid in group 1 also showed a decrease in pain with 
each recorded score, but it was not nearly as drastic a reduction as the patients in group 2.  By the 
end of the week, both groups exhibited a statistically significant (p <0.05) decrease in pain 
compared to their initial presentation.1   This trial was safe and there were no reported adverse 
reactions to treatment in either group.  There were no limitations to this study. 
Table 2.  Tezel Study: Comparison of VAS Pain Scores  
Pain Group 1(topical) Group 2 (laser) P value 
Before treatment 7.72 +/- 0.67 7.78 +/- 0.78 Not statistically 
significant 
1 day after treatment 6.19 +/- 0.76 1.34 +/- 0.76 <0.05 
4 days after treatment 3.71 +/- 0.69 0.18 +/- 0.23 <0.05 
1 week after 
treatment 
0.54 +/- 0.60 0 <0.05 
*Values are expressed as a group of means +/- standard deviation 
 In the Prasad study, 25 patients between the ages of 18 to 40 were selected for the study.  
All 25 patients completed the study.  The exclusion parameters in this study included pregnancy, 
history of systemic disease, traumatic ulcers, or ulcers currently under treatment.  The mean age 
of patients in this cohort was 27.48 years old.2  The patients in this study all had two aphthous 
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ulcers in various locations of the oral cavity.  Since every person has a different pain threshold, 
this study had each patient serve as his or her own control.  One ulcer was randomly allocated to 
be treated with a CO2 laser for 5-8 seconds while the other ulcer was treated with a placebo laser.  
Patients rated their pain score for each ulcer prior to treatment, immediately after treatment, and 
one-day post treatment.  This study was a single blind study and the patients were unaware 
which lesion was treated with the laser and which was treated with a placebo laser.  The study 
showed that prior to treatment, the mean pain scores experienced in each group were 8.48+/-0.71 
in the ulcer that was going to be treated with laser and 8.08+/-0.70 in the ulcer that was to be 
treated with placebo.  Immediately after treatment, the ulcers treated with the laser showed vast 
reduction in pain 8.48+/-0.71 to 0.68+/-0.63, whereas the ulcers treated with the placebo laser 
showed almost no variability in pain reduction.  This trial was safe and there were no reported 
adverse reactions. There were no limitations to this study. 
Table 3. Prasad Study: Comparison of Pain Scores Between Laser Group and Placebo 
Group Pain Before 
treatment 
Pain Immediately 
After treatment 
Pain 24 hours 
After Treatment 
P-Score 
Laser 8.48+/- 0.71 0.68+/- 0.63 0.28+/- 0.54 <0.001 
Placebo 8.08+/- 0.70 7.96+/-0.84 No change <0.001 
*Values are expressed as a group of means 
 The Zand study evaluated the efficacy of pain relief using a single session CO2  laser 
compared to placebo laser on aphthous ulcers.  15 patients were used in this study, with all 15 
completing the study.  Each patient in the study had two aphthous ulcers and acted as his or her 
own control during the study.  One of the two ulcers on each patient was randomly allocated to 
be treated with the carbon dioxide laser for 5-10 seconds, while the other ulcer was treated with a 
placebo laser.  This study was a single blind randomized control clinical trial.  Exclusion criteria 
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included pregnancy, any known systemic disease, or a history of receiving treatment for any 
ulcers in the past three months.  The results of the study were expressed as a mean score +/- 
standard deviation.  The mean age of patients participating in this cohort was 37.9 years old +/- 
10.9 years, with ages ranging from 24 to 56 years old.  The means of the baseline scores for pain 
were 6.2+/-1.3 and 5.4+/-1.3 for the laser group and placebo group respectively.  There was no 
statistical significant difference in baseline pain between the two groups.  Immediately following 
treatment, the laser treatment group showed a drop in pain from 5.4+/-1.3 to 0.07+/-0.3, whereas 
there was no change in pain reduction for the placebo group.  The differences between the mean 
scores of pain relief were also significant at all assessments after treatment in the laser group.  
Pain levels in the placebo group remained static until 48 hours after treatment when the mean 
pain level slowly decreased to a score around 4 at the 96-hour mark.  The P-score in this study 
was P=<0.001.  This study was designed to be a single blind study, but due to the dramatic pain 
reduction of the ulcers treated with laser therapy, it was not possible to keep patients blind to 
which ulcer was treated with laser therapy versus placebo. There were no limitations to this 
study.      
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Table 4. Zand Study: Comparison of VAS Pain Scale Laser Vs. Placebo  
 
*Confidence Interval 95%  
DISCUSSION 
 This systematic review assessed the use of laser therapy for pain relief in patients with 
recurrent aphthous stomatitis.  Currently, laser therapy for eradication of aphthous ulceration 
outbreaks is not widespread, but the data reported above demonstrates laser therapy may be the 
leading choice for reducing pain in RAS.  The results from these studies show that laser therapy 
is an effective and safe alternative treatment for RAS.  There are no problems or adverse affects 
reported from using lasers for pain reduction in patients with aphthous ulcerations.  There are no 
drug to drug interactions to worry about, or past problems with this therapy.  Laser therapy is a 
non invasive, highly precise way to treat RAS while causing minimal disturbance to surrounding 
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tissue.2  The results of all three randomized control clinical trials showed that a single session of 
laser therapy swiftly and significantly reduces pain associated with RAS.2         
CONCLUSSION 
 Laser therapy is an effective alternative for relieving pain in adult patients with recurrent 
aphthous stomatitis.  All three studies showed evidence of rapid pain relief after therapy 
compared to either placebo or topical medication.  Although laser therapy was not directly 
compared to many pain relief options used currently, laser therapy has shown to be quiet 
effective at relieving pain associated with recurrent aphthous stomatitis.  Laser therapy has also 
been shown to have no concerning adverse effects noted in any of the studies reviewed.   
 Due to the small sample sizes and limited amount of studies, it would be beneficial to 
have future studies compare pain relief from laser therapy directly to pain relief from the current 
treatment options.  Future studies should follow patients to evaluate not only pain relief from 
current aphthous stomatitis, but also evaluate if laser therapy is effective at reducing the amount 
of aphthous stomatitis that returns following laser therapy.  So far, laser therapy seems to be a 
more effective, safer, and faster treatmen at relieving pain associated with recurrent aphthous 
stomatitis.       
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